v3.26.1
Segment Information
 3 Months Ended
Jun. 30, 2026
Segment Information [Abstract]  
Segment Information
9. Segment Information
 
An operating segment is a component of an entity whose operating results are regularly reviewed by its chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance. Factors used by the Company in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance.
 
The Company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights. The Company’s CODM is its Chief Executive Officer. The accounting policies of the segment are those described in the summary of significant accounting policies.
 
The CODM assesses the performance of the segment based on net loss, which is reported on the unaudited condensed consolidated statement of net loss and comprehensive loss as Net loss and total comprehensive loss. The measure of segment assets is reported on the unaudited condensed consolidated balance sheet as total assets.
 
The Company has not generated any revenue and expects to continue to incur significant expenses and operating losses as it advances product candidates through all stages of development, and ultimately, receive regulatory approval. Accordingly, the CODM utilizes the cash budget and forecasts in assessing the entity-wide operating results and performance, and in deciding how to allocate resources across the organization and its segment. Net loss is used to monitor budgets against actual results, which then is used in assessing the performance of the segment.
The table below summarizes the significant expenses, by category regularly reviewed by the CODM, for the three months ended June 30, 2026 and 2025:
 
         
    June 30,
2026		    June 30,
2025 		 
    $    $ 
Clinical development programs
  (408)    (446) 
Professional fees
  (898)    (988) 
Salaries and benefits
  (589)    (802) 
Stock-based compensation
  (105)    (302) 
Write-off of IPR&D
  (13,533)    — 
Other general and administrative expenses (1)
  (384)    (552) 
Other segment expense (2)
  (14)    (476) 
Interest income, net
  141    204 
Income tax benefit
  —    — 
Segment and consolidated loss
  (15,790)    (3,362) 
 
1)
Other general and administrative expenses include depreciation, travel, and other administrative costs.
 
2)
Other segment expense includes change in fair value of derivative warrant liabilities and foreign exchange losses.